このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Integral Diagnostics 将来の成長

Future 基準チェック /46

Integral Diagnostics利益と収益がそれぞれ年間72.4%と6.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に11.6% 74.7%なると予測されています。

主要情報

74.9%

収益成長率

77.7%

EPS成長率

Healthcare 収益成長	19.6%
収益成長率	6.4%
将来の株主資本利益率	12.1%
アナリストカバレッジ	Good
最終更新日	17 Jun 2024

今後の成長に関する最新情報

Recent updates

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Feb 21

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Nov 22

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Feb 20

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Dec 14

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

May 26

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Feb 28

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Feb 25

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Oct 29

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Sep 13

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Jun 04

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

May 14

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

May 03

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Apr 16

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Mar 27

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

Mar 17

Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03

Here's What We Learned About The CEO Pay At Integral Diagnostics Limited (ASX:IDX)

Jan 24

Should You Use Integral Diagnostics's (ASX:IDX) Statutory Earnings To Analyse It?

Jan 14

Shareholders Of Integral Diagnostics (ASX:IDX) Must Be Happy With Their 201% Total Return

Jan 05

Is Integral Diagnostics (ASX:IDX) A Risky Investment?

Dec 26

At AU$4.30, Is It Time To Put Integral Diagnostics Limited (ASX:IDX) On Your Watch List?

Dec 17

What To Know Before Buying Integral Diagnostics Limited (ASX:IDX) For Its Dividend

Dec 08

Returns On Capital At Integral Diagnostics (ASX:IDX) Paint An Interesting Picture

Nov 29

Is Integral Diagnostics Limited's (ASX:IDX) Shareholder Ownership Skewed Towards Insiders?

Nov 19

Is Integral Diagnostics (ASX:IDX) A Risky Investment?

Sep 20

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Sep 11

Could Integral Diagnostics Limited (ASX:IDX) Have The Makings Of Another Dividend Aristocrat?

Sep 03

業績と収益の成長予測

ASX:IDX - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	535	31	46	77	12
6/30/2025	504	24	37	68	14
6/30/2024	475	-49	25	57	14
12/31/2023	456	-58	20	62	N/A
9/30/2023	449	-16	24	67	N/A
6/30/2023	441	25	27	71	N/A
3/31/2023	418	23	22	58	N/A
12/31/2022	395	21	17	45	N/A
9/30/2022	378	18	13	41	N/A
6/30/2022	361	15	9	37	N/A
3/31/2022	361	18	14	41	N/A
12/31/2021	360	22	18	44	N/A
9/30/2021	356	26	34	57	N/A
6/30/2021	351	31	49	70	N/A
3/31/2021	333	32	54	73	N/A
12/31/2020	315	32	59	76	N/A
9/30/2020	295	28	44	65	N/A
6/30/2020	276	23	28	54	N/A
3/31/2020	263	22	19	47	N/A
12/31/2019	250	21	9	39	N/A
9/30/2019	241	21	12	37	N/A
6/30/2019	232	21	15	34	N/A
3/31/2019	222	19	14	30	N/A
12/31/2018	211	17	13	26	N/A
9/30/2018	200	16	14	26	N/A
6/30/2018	189	15	15	27	N/A
3/31/2018	187	15	17	27	N/A
12/31/2017	185	15	19	27	N/A
9/30/2017	182	15	N/A	25	N/A
6/30/2017	180	15	N/A	23	N/A
3/31/2017	177	16	N/A	26	N/A
12/31/2016	175	16	N/A	30	N/A
9/30/2016	171	14	N/A	27	N/A
6/30/2016	168	11	N/A	24	N/A
3/31/2016	165	11	N/A	22	N/A
12/31/2015	162	11	N/A	20	N/A
9/30/2015	157	8	N/A	18	N/A
6/30/2015	151	5	N/A	17	N/A
6/30/2014	4	3	N/A	4	N/A
6/30/2013	3	3	N/A	4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IDXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.3% ) よりも高い成長率であると考えられます。

収益対市場: IDX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: IDX今後 3 年以内に収益を上げることが予想されます。

収益対市場: IDXの収益 ( 6.3% ) Australian市場 ( 5.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: IDXの収益 ( 6.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IDXの自己資本利益率は、3年後には低くなると予測されています ( 11.6 %)。

Integral Diagnostics 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 11%

Price target decreased by 7.5% to AU$3.05

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 16%

Consensus forecasts updated

Recent updates

First half dividend of AU$0.025 announced

First half 2024 earnings: EPS misses analyst expectations

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Consensus EPS estimates fall by 12%

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Consensus EPS estimates fall by 11%

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Price target decreased by 7.5% to AU$3.05

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings: EPS misses analyst expectations

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Consensus EPS estimates fall by 16%

Integral Diagnostics Limited Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued after recent price drop

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Independent Non-Executive Director recently bought AU$114k worth of stock

Consensus forecasts updated

Now 22% undervalued after recent price drop

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to AU$3.65

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

Now 21% undervalued after recent price drop

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Now 21% undervalued

Executive Director recently bought AU$70k worth of stock

Consensus forecasts updated

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Consensus forecasts updated

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About

Executive Director has left the company

Price target raised to AU$4.99

Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend

Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?

First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020)

Revenue beats expectations, earnings disappoint

Integral Diagnostics Limited Announces Retirement of Dr. Chien Ho as Executive Director, Effective on March 1, 2021

New 90-day high: AU$5.00